DNA X Financials
This page shows DNA X (SONM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
DNA X has shifted from near-breakeven operations to a funding-dependent balance sheet as liquidity eroded faster than profits suggest
Between FY2023 and FY2025, operating cash burn worsened from-$4.1M to-$23.5M . At the same time, cash on hand fell to$1.3M even after a financing inflow of$19.5M , which shows the business is relying on external capital to cover day-to-day cash needs rather than funding itself internally.
In FY2024, gross profit of
The balance sheet moved from positive equity of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of DNA X's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
DNA X carries a low D/E ratio of -0.64, meaning only $-0.64 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 71/100, indicating a strong balance sheet with room for future borrowing.
DNA X's current ratio of 0.57 is below the typical benchmark, resulting in a score of 6/100. This tight liquidity could limit financial flexibility if cash inflows slow.
DNA X passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, DNA X generates $1.14 in operating cash flow (-$23.5M OCF vs -$20.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
DNA X earns $-5.7 in operating income for every $1 of interest expense (-$5.4M vs $945K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
DNA X's EBITDA was -$1.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 342.0% from the prior year.
DNA X reported -$20.7M in net income in fiscal year 2025. This represents an increase of 38.6% from the prior year.
DNA X earned $-28.58 per diluted share (EPS) in fiscal year 2025. This represents an increase of 77.7% from the prior year.
Cash & Balance Sheet
DNA X held $1.3M in cash against $5.1M in long-term debt as of fiscal year 2025.
DNA X had 1M shares outstanding in fiscal year 2025. This represents an increase of 356.9% from the prior year.
Margins & Returns
Capital Allocation
SONM Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $16.2M+44.9% | $11.2M-33.1% | $16.7M+11.6% | $15.0M-0.3% | $15.0M+30.4% | $11.5M |
| Cost of Revenue | N/A | N/A | $11.9M+51.1% | $7.8M-6.2% | $8.4M-55.0% | $18.6M+104.3% | $9.1M+33.6% | $6.8M |
| Gross Profit | N/A | N/A | $1.8M+114.9% | $845K-89.9% | $8.4M+4666.1% | -$183K-104.3% | $4.2M+42.5% | $3.0M |
| R&D Expenses | N/A | N/A | $181K-80.1% | $909K-44.3% | $1.6M-86.9% | $12.5M+1649.2% | $715K+28.4% | $557K |
| SG&A Expenses | $3.6M | N/A | $3.2M-1.9% | $3.2M+270.5% | $870K+118.0% | -$4.8M-269.8% | $2.8M+16.4% | $2.4M |
| Operating Income | -$3.6M | N/A | -$4.0M+40.9% | -$6.7M-673.8% | -$870K-110.3% | $8.4M+455.0% | -$2.4M+63.3% | -$6.5M |
| Interest Expense | $131K | N/A | $339K+110.6% | $161K+126.8% | $71K | N/A | N/A | N/A |
| Income Tax | $2.5M | N/A | $90K-35.3% | $139K+5.3% | $132K+349.1% | -$53K-145.3% | $117K+216.2% | $37K |
| Net Income | $6.3M | N/A | -$4.8M+36.4% | -$7.5M-1732.1% | $458K+102.1% | -$21.6M-760.4% | -$2.5M+62.0% | -$6.6M |
| EPS (Diluted) | $5.01 | N/A | $-4.83 | $-0.79-156.0% | $1.41 | N/A | $-9.32-561.0% | $-1.41 |
SONM Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.8M-89.0% | $43.9M+9.1% | $40.2M+11.5% | $36.1M+0.3% | $36.0M-9.5% | $39.7M-19.1% | $49.1M+7.1% | $45.9M |
| Current Assets | $3.3M-88.6% | $28.9M-4.6% | $30.3M+11.7% | $27.1M+0.7% | $26.9M-16.3% | $32.2M-5.0% | $33.9M+3.9% | $32.6M |
| Cash & Equivalents | $1.2M-8.3% | $1.3M-39.0% | $2.1M+6.5% | $2.0M-5.2% | $2.1M-60.4% | $5.3M-41.0% | $9.1M-5.6% | $9.6M |
| Inventory | N/A | N/A | $11.0M+11.1% | $9.9M+14.7% | $8.6M-18.8% | $10.6M-14.2% | $12.4M+76.3% | $7.0M |
| Accounts Receivable | $57K | N/A | $3.5M+21.9% | $2.9M-40.8% | $4.8M+11.8% | $4.3M-17.2% | $5.2M-35.6% | $8.1M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.9M-90.3% | $50.6M+23.7% | $40.9M+9.4% | $37.4M+1.0% | $37.0M-18.5% | $45.4M+34.4% | $33.8M+19.0% | $28.4M |
| Current Liabilities | $4.3M-91.5% | $50.6M+30.3% | $38.9M+9.0% | $35.7M+2.8% | $34.7M-20.7% | $43.7M+35.9% | $32.2M+19.7% | $26.9M |
| Long-Term Debt | $1.1M-78.8% | $5.1M+1926.0% | $250K-91.4% | $2.9M+415.2% | $566K | N/A | N/A | N/A |
| Total Equity | -$983K+87.6% | -$8.0M-1034.8% | -$701K+47.5% | -$1.3M-23.6% | -$1.1M+81.1% | -$5.7M-137.1% | $15.3M-12.2% | $17.5M |
| Retained Earnings | -$297.6M+2.2% | -$304.3M-3.0% | -$295.4M-1.6% | -$290.6M-2.6% | -$283.1M+0.2% | -$283.6M-8.2% | -$262.0M-1.0% | -$259.5M |
SONM Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.5M-73.0% | -$2.0M+71.5% | -$7.0M-44.1% | -$4.9M+49.2% | -$9.6M-113.0% | -$4.5M-981.3% | -$417K+87.7% | -$3.4M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $8K-94.2% | $137K+251.3% | $39K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$4.5M-715.3% | -$554K+83.9% | -$3.4M |
| Investing Cash Flow | $3.4M | N/A | N/A | N/A | N/A | -$8K+94.2% | -$137K-251.3% | -$39K |
| Financing Cash Flow | N/A | $1.2M-83.7% | $7.2M+50.1% | $4.8M-25.2% | $6.4M+697.3% | $800K+5614.3% | $14K-99.6% | $3.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SONM Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 11.2%+3.7pp | 7.5%-42.4pp | 50.0%+51.2pp | -1.2%-29.4pp | 28.2%+2.4pp | 25.8% |
| Operating Margin | N/A | N/A | -24.6%+35.6pp | -60.2%-55.0pp | -5.2%-61.5pp | 56.3%+72.1pp | -15.8%+40.4pp | -56.2% |
| Net Margin | N/A | N/A | -29.3%+37.5pp | -66.8%-69.5pp | 2.7%+147.0pp | -144.3%-127.5pp | -16.7%+40.7pp | -57.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -16.4%+21.5pp | -37.9% |
| Return on Assets | 131.1% | N/A | -11.8%+8.9pp | -20.7%-22.0pp | 1.3%+55.7pp | -54.4%-49.3pp | -5.1%+9.3pp | -14.4% |
| Current Ratio | 0.76+0.2 | 0.57-0.2 | 0.78+0.0 | 0.76-0.0 | 0.78+0.0 | 0.74-0.3 | 1.05-0.2 | 1.21 |
| Debt-to-Equity | -1.09-0.5 | -0.64-0.3 | -0.36+1.8 | -2.19-1.7 | -0.52+7.4 | -7.97-10.2 | 2.20+0.6 | 1.63 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -30.1%-26.5pp | -3.7%+26.1pp | -29.8% |
Note: Shareholder equity is negative (-$8.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.57), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is DNA X profitable?
No, DNA X (SONM) reported a net income of -$20.7M in fiscal year 2025.
What is DNA X's EBITDA?
DNA X (SONM) had EBITDA of -$1.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does DNA X have?
As of fiscal year 2025, DNA X (SONM) had $1.3M in cash and equivalents against $5.1M in long-term debt.
What is DNA X's operating cash flow?
DNA X (SONM) generated -$23.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are DNA X's total assets?
DNA X (SONM) had $43.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What is DNA X's current ratio?
DNA X (SONM) had a current ratio of 0.57 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is DNA X's debt-to-equity ratio?
DNA X (SONM) had a debt-to-equity ratio of -0.64 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is DNA X's return on assets (ROA)?
DNA X (SONM) had a return on assets of -47.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is DNA X's cash runway?
Based on fiscal year 2025 data, DNA X (SONM) had $1.3M in cash against an annual operating cash burn of $23.5M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is DNA X's debt-to-equity ratio negative or unusual?
DNA X (SONM) has negative shareholder equity of -$8.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is DNA X's Piotroski F-Score?
DNA X (SONM) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are DNA X's earnings high quality?
DNA X (SONM) has an earnings quality ratio of 1.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can DNA X cover its interest payments?
DNA X (SONM) has an interest coverage ratio of -5.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is DNA X?
DNA X (SONM) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.